NO343603B1 - Forbindelse for anvendelse for behandling av søvnighet på dagtid assosiert med Parkinsons sykdom eller obstruktiv søvnapné, samt kombinasjon omfattende forbindelsen med et anti-parkinson medikament. - Google Patents

Forbindelse for anvendelse for behandling av søvnighet på dagtid assosiert med Parkinsons sykdom eller obstruktiv søvnapné, samt kombinasjon omfattende forbindelsen med et anti-parkinson medikament.

Info

Publication number
NO343603B1
NO343603B1 NO20075086A NO20075086A NO343603B1 NO 343603 B1 NO343603 B1 NO 343603B1 NO 20075086 A NO20075086 A NO 20075086A NO 20075086 A NO20075086 A NO 20075086A NO 343603 B1 NO343603 B1 NO 343603B1
Authority
NO
Norway
Prior art keywords
compound
parkinson
disease
treatment
combination
Prior art date
Application number
NO20075086A
Other languages
English (en)
Norwegian (no)
Other versions
NO20075086L (no
Inventor
Jean-Charles Schwartz
Jeanne-Marie Lecomte
Original Assignee
Bioprojet Soc Civ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35169680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO343603(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioprojet Soc Civ filed Critical Bioprojet Soc Civ
Publication of NO20075086L publication Critical patent/NO20075086L/no
Publication of NO343603B1 publication Critical patent/NO343603B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20075086A 2005-04-01 2007-10-09 Forbindelse for anvendelse for behandling av søvnighet på dagtid assosiert med Parkinsons sykdom eller obstruktiv søvnapné, samt kombinasjon omfattende forbindelsen med et anti-parkinson medikament. NO343603B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05290727A EP1707203A1 (en) 2005-04-01 2005-04-01 Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
US66861805P 2005-04-06 2005-04-06
PCT/IB2006/000739 WO2006103546A2 (en) 2005-04-01 2006-03-30 Treatment of parkinson's disease, obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine h3-receptor ligands

Publications (2)

Publication Number Publication Date
NO20075086L NO20075086L (no) 2007-12-27
NO343603B1 true NO343603B1 (no) 2019-04-08

Family

ID=35169680

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075086A NO343603B1 (no) 2005-04-01 2007-10-09 Forbindelse for anvendelse for behandling av søvnighet på dagtid assosiert med Parkinsons sykdom eller obstruktiv søvnapné, samt kombinasjon omfattende forbindelsen med et anti-parkinson medikament.

Country Status (27)

Country Link
US (1) US8486947B2 (enExample)
EP (2) EP1707203A1 (enExample)
JP (3) JP5546761B2 (enExample)
KR (1) KR101308527B1 (enExample)
CN (1) CN101171009B (enExample)
AU (1) AU2006228413C1 (enExample)
BR (1) BRPI0612216B1 (enExample)
CA (1) CA2603656C (enExample)
CY (1) CY1114636T1 (enExample)
DK (1) DK1863487T4 (enExample)
EA (1) EA016007B1 (enExample)
ES (1) ES2426008T5 (enExample)
HR (1) HRP20130748T4 (enExample)
MA (1) MA29353B1 (enExample)
ME (1) ME01713B (enExample)
MX (1) MX2007012162A (enExample)
NO (1) NO343603B1 (enExample)
NZ (1) NZ561940A (enExample)
PL (1) PL1863487T5 (enExample)
PT (1) PT1863487E (enExample)
RS (1) RS52911B2 (enExample)
SG (1) SG147415A1 (enExample)
SI (1) SI1863487T2 (enExample)
TN (1) TNSN07365A1 (enExample)
UA (1) UA94902C2 (enExample)
WO (1) WO2006103546A2 (enExample)
ZA (1) ZA200708086B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
CA2655604C (en) 2006-06-23 2016-08-09 Abbott Laboratories Cyclopropyl amine derivatives
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
MX2009000884A (es) 2006-07-25 2009-06-05 Cephalon Inc Derivados de piridizinona.
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
EP2250176B1 (en) 2008-01-30 2012-08-01 Cephalon, Inc. Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
FR2932479A1 (fr) * 2008-06-13 2009-12-18 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
US9181275B2 (en) 2011-08-11 2015-11-10 Abbvie Inc. Mercaptoamidine derivatives and methods of use
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
AU2013327450B2 (en) * 2012-10-05 2018-07-12 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
EP3391886A1 (en) 2017-04-19 2018-10-24 Novartis AG The use of a h3r inverse agonist for the treatment of shift work disorder
US11266837B2 (en) 2019-03-06 2022-03-08 Medtronic Xomed, Inc. Position sensitive lingual muscle simulation system for obstructive sleep apnea
EP4248969A1 (en) 2022-03-23 2023-09-27 Bioprojet Use of pitolisant for treating severe fatigue
CN121175294A (zh) 2023-03-31 2025-12-19 生物计划制药公司 盐酸替洛利生的多晶型形式
TW202535386A (zh) 2023-10-16 2025-09-16 法商拜爾普羅傑特醫藥有限公司 腸溶包衣必托里賽（ｐｉｔｏｌｉｓａｎｔ）調配物及使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220225A1 (en) * 1998-07-29 2004-11-04 Jean-Charles Schwartz Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5815945A (ja) * 1981-07-21 1983-01-29 Teikoku Hormone Mfg Co Ltd 新規なフエノキシアルキルアミン誘導体
FR2579596B1 (fr) 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
FR2671083B1 (fr) 1990-12-31 1994-12-23 Inst Nat Sante Rech Med Nouvelles 4-(4-imidazolyl) piperidines substituees en 1, leur preparation ainsi que leurs applications therapeutiques.
EP0573542B1 (en) 1991-02-27 1997-10-15 Seed Capital Investments( Sci) B.V. Imidazole-derivatives having antagonistic activity on the histamine h3-receptor
KR0142801B1 (en) 1991-12-18 1998-07-15 Schering Corp Imidazoylalkyl substituted with a six membered nitrogen containing heterocyclic ring t
NZ246441A (en) 1991-12-18 1996-02-27 Schering Corp Imidazol or imidazolalkyl substituted with a 4 or 5 membered nitrogen containing heterocycle, preparation and pharmaceutical compositions thereof
FR2686084B1 (fr) 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5486526A (en) * 1992-04-01 1996-01-23 The University Of Toledo Histamine H3 -receptor antagonists and therapeutic uses thereof
US5380858A (en) 1992-04-01 1995-01-10 The University Of Toledo Process for the preparation of intermediates useful for the synthesis of histamine receptor antagonists
US5639775A (en) 1992-04-01 1997-06-17 The University Of Toledo 4-[4'-piperodinyl or 3'-pirrolidinyl] substituted imidazoles as H3 -receptor antagonists and therapeutic uses thereof
EP0680960A4 (en) 1993-01-25 1997-05-14 Green Cross Corp IMIDAZOLE CONNECTION.
JP3522790B2 (ja) 1993-06-08 2004-04-26 花王株式会社 Ｈ３−レセプター刺激薬
AU7823894A (en) 1993-08-27 1995-03-21 Vrije Universiteit New imidazole derivatives having agonistic or antagonistic activity on the histamine h3 receptor
GB9319534D0 (en) * 1993-09-22 1993-11-10 Boots Co Plc Therapeutic agents
NZ276883A (en) 1993-11-15 1998-08-26 Schering Corp 1h-imidazol-4-yl)alkyl]benzene derivatives
GB9411045D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Compounds and use
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
PT841922E (pt) 1995-05-30 2002-07-31 Gliatech Inc Derivados de ih-imidazole 4(5)-substituidos
US5652258A (en) 1995-05-30 1997-07-29 Gliatech, Inc. 2-(4-imidazoyl) cyclopropyl derivatives
ES2184876T3 (es) 1995-06-07 2003-04-16 Gliatech Inc Derivados de imidazol sustituidos en 1h-4(5).
AU709611B2 (en) 1996-02-09 1999-09-02 James Black Foundation Limited Histamine h3 receptor ligands
JP3925579B2 (ja) * 1998-02-03 2007-06-06 日本精工株式会社 潤滑剤供給体、並びに前記潤滑剤供給体を備える転がり軸受、リニアガイド装置及びボールねじ装置
US6136559A (en) * 1998-10-07 2000-10-24 Ortho Pharmaceutical Corporation DNA encoding as human histamine receptor of the H3 subtype
AU770234B2 (en) * 1999-06-11 2004-02-19 Toyama Chemical Co. Ltd. N-alkoxyalkyl-N, N-dialkylamine derivatives or salts thereof and agents for treating neurodegenerative diseases comprising the same
GB9924941D0 (en) * 1999-10-22 1999-12-22 Univ Manchester Treatment of dyskinesia
US6620839B2 (en) * 2000-07-13 2003-09-16 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
ATE319696T1 (de) * 2000-08-08 2006-03-15 Ortho Mcneil Pharm Inc Nicht-imidazol aryloxyalkylamine als h3 rezeptor liganden
CA2419073A1 (en) * 2000-08-17 2002-02-21 Gliatech, Inc. Novel alicyclic imidazoles as h3 agents
AU2001283573A1 (en) * 2000-08-21 2002-03-04 Gliatech, Inc. The use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity
CA2442326C (en) * 2001-03-29 2012-05-22 Ortho-Mcneil Pharmaceutical, Inc. Imidazolyl derivatives useful as histamine h3 receptor ligands
AU2002228698A1 (en) * 2001-11-15 2003-06-10 Ortho-Mcneil Pharmaceutical, Inc. Agonists of recombinant human histamine h3 receptor
CA2469893A1 (en) * 2001-12-10 2003-06-19 Ortho-Mcneil Pharmaceutical, Inc. Phenylalkynes
EP1556046A1 (en) * 2002-10-23 2005-07-27 Janssen Pharmaceutica N.V. Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators
FR2856596B1 (fr) * 2003-06-27 2007-04-27 Bioprojet Soc Civ Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes.
CA2529790A1 (en) * 2003-06-27 2005-01-27 Banyu Pharmaceutical Co., Ltd. Heteroaryloxy nitrogenous saturated heterocyclic derivative
SE0302116D0 (sv) * 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
JP4765627B2 (ja) * 2003-09-22 2011-09-07 Ｍｓｄ株式会社 新規ピペリジン誘導体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220225A1 (en) * 1998-07-29 2004-11-04 Jean-Charles Schwartz Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Meier G. et al: "A novel non-imidazole histamine H3 receptor antagonist with high in vitro and oral in vivo potency», Arch. Pharm. Med. Chem 334, suppl. 2, 1-89 (2001), sammendrag C40, Dated: 01.01.0001 *
Passani, Maria Beatrice et al.: "The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders", TRENDS in Pharmacological Sciences, vol. 25 (2004), side 618-625, Dated: 01.01.0001 *

Also Published As

Publication number Publication date
SG147415A1 (en) 2008-11-28
WO2006103546A3 (en) 2007-03-01
JP5546761B2 (ja) 2014-07-09
CY1114636T1 (el) 2016-10-05
JP2014062126A (ja) 2014-04-10
SI1863487T2 (sl) 2019-11-29
DK1863487T4 (da) 2019-10-14
KR101308527B1 (ko) 2013-09-17
TNSN07365A1 (fr) 2008-12-31
CA2603656A1 (en) 2006-10-05
CN101171009B (zh) 2012-11-07
NO20075086L (no) 2007-12-27
AU2006228413B2 (en) 2011-09-15
RS52911B (sr) 2014-02-28
RS52911B2 (sr) 2019-11-29
EP1863487A2 (en) 2007-12-12
HRP20130748T1 (en) 2013-10-11
UA94902C2 (ru) 2011-06-25
PL1863487T3 (pl) 2014-10-31
KR20080002904A (ko) 2008-01-04
EA016007B1 (ru) 2012-01-30
US8486947B2 (en) 2013-07-16
ME01713B (me) 2014-09-20
AU2006228413A1 (en) 2006-10-05
BRPI0612216A2 (pt) 2010-10-26
HRP20130748T4 (hr) 2019-11-15
EP1863487B2 (en) 2019-07-17
JP5955872B2 (ja) 2016-07-20
ES2426008T3 (es) 2013-10-18
AU2006228413C1 (en) 2012-02-02
JP2016106142A (ja) 2016-06-16
DK1863487T3 (da) 2013-08-12
EP1707203A1 (en) 2006-10-04
ZA200708086B (en) 2008-10-29
WO2006103546A2 (en) 2006-10-05
CN101171009A (zh) 2008-04-30
EA200702135A1 (ru) 2008-04-28
JP2008534572A (ja) 2008-08-28
MX2007012162A (es) 2007-11-22
PT1863487E (pt) 2013-08-29
BRPI0612216B1 (pt) 2022-04-19
MA29353B1 (fr) 2008-03-03
EP1863487B1 (en) 2013-05-29
SI1863487T1 (sl) 2013-09-30
ES2426008T5 (es) 2020-03-20
US20090318433A1 (en) 2009-12-24
NZ561940A (en) 2010-06-25
CA2603656C (en) 2015-06-16
PL1863487T5 (pl) 2021-08-09

Similar Documents

Publication Publication Date Title
IL178390A0 (en) Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
NO20054640D0 (no) Fremgangsmater for behandling av Parkinsons sykdom
ZA200708086B (en) Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands
NO20082067L (no) Nye pyrimidinderivater og deres anvendelse i terapi, samt anvendelse av pyrimidinderivater for fremstilling av et legemiddel for å forebygge og/eller behandle Alzheimers sykdom
WO2006116177A3 (en) Mouth guard
CL2007001030A1 (es) Compuestos derivados de heterociclilguanidina; y composicion farmaceutica, util para el tratamiento de la enfermedad de alzheimer, demencia senil y demencia asociada a enfermedad de parkinson entre otras.
PL1673352T3 (pl) Sulfoksyiminopodstawione pirymidyny jako inhibitory CDK i/lub VEGF, ich wytwarzanie i zastosowanie jako środków leczniczych
IL177787A0 (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
NO20052420D0 (no) Farmakologisk behandling av sovnapn±.
ATE372998T1 (de) 1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
JP2007523135A5 (enExample)
AP2006003688A0 (en) 1,3-dioxane derivatives and analogues thereof useful in the treatment of I.A obesity and diabetes
EP1948831A4 (en) ALZHEIMER ASSOCIATED GENETIC POLYMORPHISMS, DETECTION METHOD AND USE THEREOF
DE602006001590D1 (de) 7-(2-(4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyrid-1-yl)ethyl)isochinolin-besylatsalz, dessen herstellung und dessen therapeutische verwendung
JP2008519810A5 (enExample)
PL1890695T3 (pl) Zastosowanie 2,5-dipodstawionych pochodnych tiazol-4-onu w lekach
FR2912404B1 (fr) Derives d'azabicycloalkane,leur preparation et leur application en therapeutique.
ATE448211T1 (de) 1,2,4-triazinderivate, ihre herstellung und ihre verwendung in der humantherapie
IL182125A0 (en) Optically active 4,4-di-substituted oxazolidine derivatives and processes for the preparation thereof
USD527680S1 (en) Whimsical mouse spinner
IL196179A0 (en) Identification and use of gprc variants in the treatment and diagnosis of parkinson's disease
Warner Perioperative Management of the Patient With Respiratory Disease
Jones Charting the Development of the History of Psychology
HK1119947A (zh) 嘧啶衍生物在制造用於防止和/或治疗阿兹海默氏症的药物中的用途
HK1120037A (en) New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease